XML 17 R5.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONSOLIDATED STATEMENTS OF CHANGES IN MEZZANINE AND SHAREHOLDERS’ EQUITY - USD ($)
$ in Thousands
Total
Performance-Based Restricted Stock Units (PSUs)
Class A Common Stock
Class A Common Stock
Performance-Based Restricted Stock Units (PSUs)
Additional Paid-In Capital
Additional Paid-In Capital
Performance-Based Restricted Stock Units (PSUs)
Accumulated Other Comprehensive Income (Loss)
Retained Earnings (Accumulated Deficit)
Treasury Stock
Series A preferred stock , beginning balance (in shares) at Dec. 31, 2022 0                
Series A preferred stock , Beginning balance at Dec. 31, 2022 $ 0                
Increase (Decrease) in Temporary Equity [Roll Forward]                  
Issuance of series A preferred stock, net of issuance costs (in shares) 175,000                
Issuance of series A preferred stock, net of issuance costs $ 168,000                
Net loss attributable to common shareholders of Evolent Health, Inc. $ 2,625                
Series A preferred stock , Ending balance (in shares) at Mar. 31, 2023 175,000                
Series A preferred stock , Ending balance at Mar. 31, 2023 $ 170,625                
Beginning balance (in shares) at Dec. 31, 2022     101,501,000            
Beginning balance at Dec. 31, 2022 859,417   $ 1,015   $ 1,486,857   $ (1,178) $ (606,154) $ (21,123)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Stock-based compensation expense 10,710       10,710        
Exercise of stock options (in shares)     330,000            
Exercise of stock options 1,581   $ 3   1,578        
Restricted stock units vested, net of shares withheld for taxes (in shares)     434,000            
Restricted stock units vested, net of shares withheld for taxes (8,632)   $ 4   (8,636)        
Stock units vested, net of shares withheld for taxes (in shares)     760,000 202,000          
Stock units vested, net of shares withheld for taxes 0 $ (3,975) $ 8 $ 2 (8) $ (3,977)      
Shares issued for acquisition (in shares)     8,475,000            
Shares issued for acquisition 261,271   $ 85   261,186        
Class A common stock issued for payment of earn-outs (in shares)     850,000            
Class A common stock issued for payment of earn-outs 27,573   $ 8   27,565        
Foreign currency translation adjustment 56           56    
Net loss attributable to common shareholders of Evolent Health, Inc. (26,258)       (6,276)     (19,982)  
Ending balance (in shares) at Mar. 31, 2023     112,552,000            
Ending balance at Mar. 31, 2023 $ 1,121,743   $ 1,125   1,768,999   (1,122) (626,136) (21,123)
Series A preferred stock , beginning balance (in shares) at Dec. 31, 2023 175,000                
Series A preferred stock , Beginning balance at Dec. 31, 2023 $ 178,427                
Increase (Decrease) in Temporary Equity [Roll Forward]                  
Net loss attributable to common shareholders of Evolent Health, Inc. $ 2,867                
Series A preferred stock , Ending balance (in shares) at Mar. 31, 2024 175,000                
Series A preferred stock , Ending balance at Mar. 31, 2024 $ 181,294                
Beginning balance (in shares) at Dec. 31, 2023 115,424,833   115,425,000            
Beginning balance at Dec. 31, 2023 $ 1,067,701   $ 1,154   1,808,121   (1,257) (719,194) (21,123)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Stock-based compensation expense 18,786       18,786        
Exercise of stock options (in shares)     96,000            
Exercise of stock options 1,059   $ 1   1,058        
Restricted stock units vested, net of shares withheld for taxes (in shares)     469,000            
Restricted stock units vested, net of shares withheld for taxes (9,770)   $ 5   (9,775)        
Stock units vested, net of shares withheld for taxes (in shares)       205,000          
Stock units vested, net of shares withheld for taxes   $ (4,564)   $ 2   $ (4,566)      
Foreign currency translation adjustment (51)           (51)    
Net loss attributable to common shareholders of Evolent Health, Inc. $ (25,225)       (7,945)     (17,280)  
Ending balance (in shares) at Mar. 31, 2024 116,195,270   116,195,000            
Ending balance at Mar. 31, 2024 $ 1,047,936   $ 1,162   $ 1,805,679   $ (1,308) $ (736,474) $ (21,123)